COMPANY RESEARCHSells ED-1 instruments and operates the ED-CRO sample submission structure determination service. The commercial service has been separately confirmed for this record.
Date is the investor report date; the earlier CHF 2.5 million in 2021 is not the latest round.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
The ED-CRO page explicitly offers contracted feasibility assessment, sample preparation, measurement, structure solution, refinement, and reporting without requiring an instrument purchase.
Accepts APIs, polymorphs, hydrates, solvates, salts, and cocrystals, with supporting crystallization and microcrystalline impurity studies.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| MicroED / 3D ED service capabilities | Determined by the submitted sample and research question · Not applicable; service capability | Services / platform | Not applicable; not a human clinical program |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Crystal Pharmatech’s November 4 announcement confirms ED-1 service in Suzhou. Its service page describes integration with solid-form screening for small crystals and pharmaceutical solid forms.
This article explores how Microcrystal Electron Diffraction (MicroED) is set to revolutionize drug polymorph research workflows. Drawing upon recent news, official websites, and LinkedIn updates from Crystal Pharmatech and Eldico, it clearly distinguishes between verified facts, industry viewpoints, and information pending verification.
Direct Electron lists a REyes webinar for November 10, 2026, at noon Eastern Time. It will discuss diffraction-guided screening, automated acquisition and structure solution, including integration with SerialEM.
The NYSBC, SEMC, and NCCAT course is scheduled for November 2–4, 2026, in New York. Its November 4 agenda includes automation and machine learning, microscope setup, acquisition, and direct-detector practicals, with optional practice on November 5.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.